切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2020, Vol. 16 ›› Issue (01) : 1 -7. doi: 10.3877/cma.j.issn.1673-5250.2020.01.001

所属专题： 文献；

述评

早产儿临床管理中的热点问题探讨
李晋辉1, 母得志1,†()   
  1. 1. 四川大学华西第二医院儿科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
  • 收稿日期:2020-01-01 修回日期:2020-01-25 出版日期:2020-02-01
  • 通信作者: 母得志

Hot issues in clinical management of premature infants

Jinhui Li1, Dezhi Mu1,†()   

  1. 1. Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2020-01-01 Revised:2020-01-25 Published:2020-02-01
  • Corresponding author: Dezhi Mu
  • About author:
    Corresponding author: Mu Dezhi, Email:
  • Supported by:
    Key Program of National Natural Science Foundation of China(81630038); National Key Clinical Specialty (Neonatal Specialty) Development Program(1311200003303)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李晋辉, 母得志. 早产儿临床管理中的热点问题探讨[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(01): 1-7.

Jinhui Li, Dezhi Mu. Hot issues in clinical management of premature infants[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(01): 1-7.

随着围生医学的发展及危重新生儿救治水平的提高，早产儿存活率逐年提升，早产儿临床管理流程亦日益规范。但是，在具体治疗方案上，尤其是对超早产儿(EPI)救治及早产儿心脏与肺部疾病等治疗方面，仍然存在一定争议。临床医师在对早产儿疾病诊疗过程中，一方面要遵循规范化的指南管理，另一方面亦须结合患儿实际情况反复权衡利弊，选择最适宜的治疗方式。笔者拟就EPI救治、早产儿动脉导管未闭(PDA)救治、糖皮质激素防治早产儿支气管肺发育不良(BPD)及一氧化氮(NO)应用于早产儿持续性肺动脉高压(PPHN)等热点问题的最新研究进展及存在问题进行阐述。

关键词: 动脉导管未闭, 支气管肺发育不良, 高血压，肺性, 糖皮质激素类, 一氧化氮, 婴儿，早产, 婴儿，极低出生体重

With the development of perinatal medicine and treatment levels of critical newborns, the survival rate of preterm infants has been improved rapidly. And clinical management processes of preterm infants have become increasingly standardized. However, there are still some controversies on the specific treatment plans, especially on treatment of extremely preterm infants (EPI) and cardiopulmonary diseases of preterm infants. In the process of diagnosis and treatment of premature diseases, clinicians should follow standardized guidelines for management, and repeatedly weigh the advantages and disadvantages based on the practical situations of preterm infants, and finally choose the most appropriate treatment for premature infants. This article will summarize the latest research progresses and existing problems of hot issues, such as treatment of EPI and patent ductus arteriosus (PDA) of preterm infants, glucocorticoids for prevention and treatment of preterm infants with bronchopulmonary dysplasia (BPD), and nitric oxide (NO) in treatment of preterm infants with persistent pulmonary hypertension (PPHN), etc..

Key words: Ductus arteriosus, patent, Bronchopulmonary dysplasia, Hypertension, pulmonary, Glucocorticoids, Nitric oxide, Infant, premature, Infant, very low birth weight
[1]
Blencowe H, Cousens S, Chou D, et al. Born too soon: the global epidemiology of 15 million preterm births[J]. Reprod Health, 2013, 10 (Suppl 1): S2. DOI: 10.1186/1742-4755-10-S1-S2.
[2]
Between-hospital variation in treatment and outcomes in extremely preterm infants[J]. N Engl J Med, 2015, 372(25): 2469. DOI: 10.1056/NEJMx150023.
[3]
Perlman J. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists[J]. Obstet Gynecol, 2014, 124(3): 635. DOI: 10.1097/AOG.0000000000000439.
[4]
中华医学会妇产科学分会产科学组. 早产临床诊断与治疗指南(2014)[J]. 中华妇产科杂志，2014, 49(7): 481-485. DOI：.3760/cma.j.issn.0529-567x.2014.07.001.
[5]
Ishii N, Kono Y, Yonemoto N, et al. Outcomes of infants born at 22 and 23 weeks′ gestation[J]. Pediatrics, 2013, 132(1): 62-71. DOI: 10.1542/peds.2012-2857.
[6]
Vavasseur C, Foran A, Murphy JF. Consensus statements on the borderlands of neonatal viability: from uncertainty to grey areas[J]. Ir Med J, 2007, 100(8): 561-564.
[7]
Burzi V, Tealdi G, Boyd RN, et al. Action observation in infancy: implications for neuro-rehabilitation[J]. Dev Med Child Neurol, 2016, 58(Suppl 4): 74-77. DOI: 10.1111/dmcn.13048.
[8]
中国医师协会儿童健康专业委员会第一届儿童早期健康发展专业委员会，中国医师协会第一届儿童早期健康发展专业委员会、西安医学会新生儿学分会. 早产儿出院后随访及管理建议[J]. 中国妇幼健康研究，2019, 30(9): 1048-1052. DOI: 10.3969/j.issn.1673-5293.2019.09.002.
[9]
Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants[J]. Cochrane Database Syst Rev, 2008, (1): CD003951. DOI: 10.1002/14651858.CD003951.pub2.
[10]
Hu Y, Jin H, Jiang Y, et al. Prediction of therapeutic response to cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus[J]. Pediatr Cardiol, 2018, 39(4): 647-652. DOI: 10.1007/s00246-018-1831-x.
[11]
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants[J]. Cochrane Database Syst Rev, 2015, (2): CD003481. DOI: 10.1002/14651858.CD003481.pub6.
[12]
Benitz WE. Patent ductus arteriosus in preterm infants[J]. Pediatrics, 2016, 137(1): e20153730. DOI: 10.1542/peds.2015-3730.
[13]
Hundscheid T, Onland W, van Overmeire B, et al. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial)[J]. BMC Pediatr, 2018, 18(1): 262. DOI: 10.1186/s12887-018-1215-7.
[14]
Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants[J]. Cochrane Database Syst Rev, 2010, (7): CD000174. DOI: 10.1002/14651858.CD000174.pub2.
[15]
Gournay V, Savagner C, Thiriez G, et al. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants[J]. Lancet, 2002, 359(9316): 1486-1488. DOI: 10.1016/S0140-6736(02)08424-6.
[16]
Weisz DE, Giesinger RE. Surgical management of a patent ductus arteriosus: is this still an option？[J]. Semin Fetal Neonatal Med, 2018, 23(4): 255-266. DOI: 10.1016/j.siny.2018.03.003.
[17]
Reese J, Scott TA, Patrick SW. Changing patterns of patent ductus arteriosus surgical ligation in the United States[J]. Semin Perinatol, 2018, 42(4): 253-261. DOI: 10.1053/j.semperi.2018.05.008.
[18]
Sankar MN, Bhombal S, Benitz WE. PDA: To treat or not to treat[J]. Congenit Heart Dis, 2019, 14(1): 46-51. DOI: 10.1111/chd.12708.
[19]
田方，石文静. 胎龄<28周早产儿动脉导管未闭的治疗进展[J]. 中国当代儿科杂志，2015, 17(10): 1142-1147. DOI: 10.7499/j.issn.1008-8830.2015.10.025.
[20]
Mandell EW, Kratimenos P, Abman SH, et al. Drugs for the prevention and treatment of bronchopulmonary dysplasia[J]. Clin Perinatol, 2019, 46(2): 291-310. DOI: 10.1016/j.clp.2019.02.011.
[21]
Doyle LW, Cheong JL, Ehrenkranz RA, et al. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants[J]. Cochrane Database Syst Rev, 2017, (10): CD001146. DOI: 10.1002/14651858.CD001146.pub5.
[22]
Doyle LW, Cheong JL, Ehrenkranz RA, et al. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants[J]. Cochrane Database Syst Rev, 2017, (10): CD001145. DOI: 10.1002/14651858.CD001145.pub4.
[23]
Onland W, De Jaegere AP, Offringa M, et al. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants[J]. Cochrane Database Syst Rev, 2017, 1: CD010941. DOI: 10.1002/14651858.CD010941.pub2.
[24]
Bassler D, van den Anker J. Inhaled drugs and systemic corticosteroids for bronchopulmonary dysplasia[J]. Pediatr Clin North Am, 2017, 64(6): 1355-1367. DOI: 10.1016/j.pcl.2017.08.012.
[25]
American Academy of Pediatrics, Watterberg KL. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia[J]. Pediatrics, 2010, 126(4): 800-808. DOI: 10.1542/peds.2010-1534.
[26]
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome - 2016 update[J]. Neonatology, 2017, 111(2): 107-125. DOI: 10.1159/000448985.
[27]
Doyle LW, Cheong J. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia - Who might benefit？[J]. Semin Fetal Neonatal Med, 2017, 22(5): 290-295. DOI: 10.1016/j.siny.2017.07.003.
[28]
申昆玲，邓力，李云珠，等. 糖皮质激素雾化吸入疗法在儿科应用的专家共识[J]. 临床儿科杂志，2018, 36(2): 95-106. DOI: 10.3969/j.issn.1000-3606.2018.02.004.
[29]
Yeh TF, Chen CM, Wu SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2016, 193(1): 86-95. DOI：10.1164/rccm.201505-0861OC.
[30]
Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia[J]. J Pediatr, 2017, 188: 24-34.e1. DOI: 10.1016/j.jpeds.2017.05.029.
[31]
Arsan S, Korkmaz A, Oğuz S. Turkish Neonatal Society guideline on prevention and management of bronchopulmonary dysplasia[J]. Turk Pediatri Ars, 2018, 53(Suppl 1): S138-S150. DOI: 10.5152/TurkPediatriArs.2018.01814.
[32]
Stewart DL, Vogel PA, Jarrett B, et al. Effect of inhaled nitric oxide on oxygen therapy, mechanical ventilation, and hypoxic respiratory failure[J]. Minerva Pediatr, 2018, 70(1): 51-58. DOI: 10.23736/S0026-4946.17.04944-1.
[33]
Lai MY, Chu SM, Lakshminrusimha S, et al. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn[J]. Pediatr Neonatol, 2018, 59(1): 15-23. DOI: 10.1016/j.pedneo.2016.09.011.
[34]
Kinsella JP, Truog WE, Walsh WF, et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn[J]. J Pediatr, 1997, 131(1 Pt 1): 55-62. DOI: 10.1016/s0022-3476(97)70124-0.
[35]
Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants[J]. Cochrane Database Syst Rev, 2017, (1): CD000509. DOI: 10.1002/14651858.CD000509.pub5.
[36]
Sokol GM, Konduri GG, Van Meurs KP. Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant[J]. Semin Perinatol, 2016, 40(6): 356-369. DOI: 10.1053/j.semperi.2016.05.007.
[37]
Dani C, Pratesi S. Nitric oxide for the treatment of preterm infants with respiratory distress syndrome[J]. Expert Opin Pharmacother, 2013, 14(1): 97-103. DOI: 10.1517/14656566.2013.746662.
[38]
李晋辉，伍金林，母得志. 吸入一氧化氮治疗早产儿低氧性呼吸衰竭的应用[J]. 中国当代儿科杂志，2013, 15(12)：1100-1103. DOI: 10.7499/j.issn.1008-8830.2013.12.016.
[39]
Hamon I, Fresson J, Nicolas MB, et al. Early inhaled nitric oxide improves oxidative balance in very preterm infants[J]. Pediatr Res, 2005, 57(5 Pt 1): 637-643. DOI: 10.1203/01.PDR.0000156507.03879.19.
[40]
中国医师协会新生儿科医师分会. 一氧化氮吸入治疗在新生儿重症监护病房的应用指南(2019版)[J/CD]. 发育医学电子杂志，2019, 7(4): 241-248. DOI: 10.3969/j.issn.2095-5340.2019.04.001.
[41]
Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome[J]. N Engl J Med, 2003, 349(22)：2099-2107. DOI: 10.1056/NEJMoa031154.
[42]
Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure[J]. N Engl J Med, 2006, 355(4): 354-364. DOI: 10.1056/NEJMoa060442.
[43]
Rhee CJ, Sriram S, Ionchev A, et al. Acute haemodynamic effects of inhaled nitric oxide in premature infants with mild-to-moderate respiratory distress[J]. Arch Dis Child Fetal Neonatal Ed, 2013, 98(2): F183-F184. DOI: 10.1136/archdischild-2012-302308.
[1] 陈腊青, 林佳佳, 毛洪刚, 童冠海, 汪梦娜, 夏红波, 刘卓, 徐海霞, 赵玉华, 张传领. 血清细胞因子及呼出气一氧化氮在哮喘-慢性阻塞性肺疾病重叠综合征中的临床意义[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 316-320.
[2] 杨皓媛, 龚杰, 邹青伟, 阮航. 哮喘孕妇的母婴不良妊娠结局研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 522-529.
[3] 靳茜雅, 黄晓松, 谭诚, 蒋琴, 侯昉, 李瑶悦, 徐冰, 贾红慧, 刘文英. 产前他克莫司治疗对先天性膈疝大鼠病理模型肺血管重构的影响[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 428-436.
[4] 胡诤贇, 史建伟, 申建伟, 王冰, 蒋春苗, 刘冲. 基于机器学习鉴定早产儿支气管肺发育不良的关键基因[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 446-454.
[5] 张伟, 王莉, 安彩霞, 王俭勤. 不同辐射防护措施对降低儿童先天性心脏病介入诊疗过程中辐射剂量的应用价值[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 455-463.
[6] 李敏, 熊菲. 母乳成分及其影响因素的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 267-272.
[7] 周美岑, 王华, 母得志. 早产儿疫苗预防接种及时性[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 261-266.
[8] 李聪, 徐艳, 吴铭, 丁瑞东, 王军. 极低出生体重儿出生时血清25-羟维生素D水平与其生后早期喂养不耐受关系的临床分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 309-314.
[9] 苏永维, 陈果. 早产儿非心脏手术的麻醉管理[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 139-144.
[10] 杨萍, 许世敏, 李亮亮, 尹向云, 锡洪敏, 马丽丽, 李向红. 早产儿支气管肺发育不良合并代谢性骨病的影响因素[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 202-211.
[11] 张霭润, 招嘉樑, 李管明, 李嘉鸿, 陈静蓉, 王兰, 庄思齐, 房晓祎. 早产儿RhE合并Rhc溶血病1例并文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 93-99.
[12] 张雯, 徐宏燕, 张彦春, 刘凯波. 2017—2021年北京市先天性心脏病流行病学资料分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 61-68.
[13] 张璐, 杨惠娟, 刘凯波. 2015—2021年北京市辅助生殖技术助孕活产及高龄孕母占比与不良妊娠结局变化趋势[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 46-53.
[14] 刁正文, 徐愈畅, 张杰, 张华军, 李秋霖, 陈卉. β-七叶皂苷钠联合甘油果糖治疗脑出血的临床效果分析[J]. 中华神经创伤外科电子杂志, 2023, 09(01): 32-37.
[15] 汪颖, 李沛霖, 李泉, 狄红梅, 高昶. 呼出气一氧化氮监测诊断幽门螺杆菌感染的有效性研究[J]. 中华胃肠内镜电子杂志, 2023, 10(01): 37-40.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号